Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

| Medicines | WHO Guidelines (TPT '24) | WHO Guidelines (Children & Adolescent '22) | EMLcsubmitted | EMLc (2023) | WHO PQ EOI (2024) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (July 2024) | Global Fund ERP recommended | GDF Catalog |
|--|-----------------------------|--|---------------|-------------|----------------------|--------------------------------|---------------|---|------------------------------------|--------------------------------|-------------|
| Isoniazid 50mg dispersible tablet | | | | | | | | | | | |
| Isoniazid 100mg dispersible tablet | | | | | | | | | | | |
| Isoniazid 100mg tablet | | | | | | | | | | | |
| Isoniazid 300mg tablet/capsule | | | | | | | | | | | |
| Levofloxacin 100mg dispersible tablet | | | | | | | | | | | |
| Rifampicin 20mg/mL oral liquid | | | | | | | | | | | |
| Rifampicin/Isoniazid 75/50 dispersible tablet | | | | | | | | | | | |
| Rifapentine 150mg dispersible tablet | | | | | | | | | | | |

LTBI: Latent TB Infection EML: Essential Medicines List **EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status Yes No

N/A

Ineligible for inclusion



Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

| Medicines | WHO Guidelines (TPT '24) | WHO Guidelines (Children & Adolescent '22) | EMLcsubmitted | EMLc (2023) | WHO PQ EOI (2024) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (July 2024) | Global Fund ERP recommended | GDF Catalog | Status Yes No Ineligible for inclusion N/A |
|---|-----------------------------|--|---------------|-------------|----------------------|--------------------------------|---------------|---|------------------------------------|--------------------------------|-------------|--|
| Rifapentine 150mg tablet | | | | | | | | | | | | |
| Rifapentine 300mg | | | | | | | | | | | | |
| Rifapentine/Isoniazid 300mg/300mg tablet | | | | | | | | | | | | |
| Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 400/80/150/ 12.5mg tablet | | | | | | | | | | | | |

LTBI: Latent TB Infection **EML:** Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







